Results 241 to 250 of about 12,220,634 (288)
Some of the next articles are maybe not open access.
In Defense of Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Not ...
Belladelli, Federico +2 more
openaire +3 more sources
ADMET considerations for phosphodiesterase-5 inhibitors
Expert Opinion on Drug Metabolism & Toxicology, 2012ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling is an important aspect of all drug developments. The pharmaceutical industry must always consider ADMET properties in order to optimize drug candidates and to introduce new formulations against existing marketed drugs.
Mohammad Amin, Rezvanfar +2 more
openaire +2 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources
Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design, 2009PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in once-daily ...
Giannitsas, Konstantinos +1 more
openaire +2 more sources
Reno-protective effects of Phosphodiesterase 5 inhibitors
Clinical and Experimental Nephrology, 2021The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation, and red blood cell genesis. Kidney disease can be caused by various factors, including diabetes, ischemia/reperfusion injury, and nephrotoxic agents.
Enis Rauf Coskuner, Burak Ozkan
openaire +2 more sources
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Annals of Pharmacotherapy, 2005OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED). DATA SOURCES Primary research and review ...
Stephen M, Setter +4 more
openaire +2 more sources
A chemometric study of phosphodiesterase 5 inhibitors
Journal of Molecular Graphics and Modelling, 2006This work presents a chemometric classification for a set of phosphodiesterase 5 inhibitors, based on a pattern recognition method widely used in quantitative structure-activity (QSAR) studies, hierarchical cluster analysis (HCA) and principal component analysis (PCA), aiming to access the most relevant structural and physicochemical variables related ...
Luciana Jansen, de O Figueiredo +4 more
openaire +2 more sources
Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design, 2006Phosphodiesterase 5 inhibitors, such as sildenafil, vardenafil and tadalafil, are now approved for the treatment of erectile dysfunction. They inhibit the cGMP-specific isoform 5 of phosphodiesterase, resulting in cGMP accumulation, which, for example in smooth muscle cells, reduces muscular tone.
Thorsten, Reffelmann, Robert A, Kloner
openaire +2 more sources
Phosphodiesterase-5 inhibitors and their hemodynamic effects
Current Hypertension Reports, 2006Erectile dysfunction occurs commonly in untreated and treated hypertensive patients, impairing adherence to treatment and quality of life. Furthermore, it is a marker for enhanced risk for cardiovascular disease. Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, provide effective treatment of erectile dysfunction.
openaire +2 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources